Enhanced CAR T-cell therapy shows early promise for B-cell cancers in first-in-human trial

A Phase I clinical trial at Ohio State University demonstrated early positive outcomes using an enhanced CAR T-cell therapy targeting three proteins (CD19, CD20, CD22) with OX40 to boost immune response for treatment-resistant B-cell blood cancers. The trial also showed the feasibility of a faster six-day manufacturing process, resulting in clinical activity and minimal side effects.

This Wire brief sits within Fusion42's coverage of Biotech.